Development of Novel Therapies for Pulmonary Hypertension by Clinical Application of Basic Research
Development of Novel Therapies for Pulmonary Hypertension by Clinical Application of Basic Research
复制标题
通过基础研究的临床应用开发肺动脉高压的新疗法
DOI：
--
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
H. Shimokawa
中科院分区：
文献类型：
--
作者：
K. Satoh;H. Shimokawa
肺动脉高压是一种致命性疾病，炎症和氧化应激与疾病状态密切相关。我们最近筛选了新的致病分子，并针对这些分子进行了药物发现。为了证实其临床意义，我们使用患者的血液样本来评估其作为诊断和预后生物标志物的潜力。最后，我们进行了高通量筛选，找到了致病蛋白的抑制剂。本章主要介绍肺动脉高压致病蛋白筛查的基础和临床研究的最新进展。
Pulmonary hypertension is a lethal disease in which inflammation and oxidative stress are deeply involved in the disease state. We have recently screened novel pathogenic molecules and have performed drug discovery targeting those molecules. To confirm its clinical significance, we used patient-derived blood samples to evaluate the potential as a biomarker for diagnosis and prognosis. Finally, we conducted a high-throughput screening and found inhibitors for the pathogenic proteins. In this chapter, we would like to introduce the recent progress on the basic and clinical research focusing on the screening of pathogenic proteins in pulmonary hypertension.
影响因子：
20.1
作者：
Rabinovitch M;Guignabert C;Humbert M;Nicolls MR
通讯作者：
Nicolls MR